pharmaceutical intermediates Letrozole

E-mail: [email protected] Skype: ycgc1992 Letrozole CAS :112809-51-5 MF: C17H11N5 MW: 285.3 Assay: 99% Appearance: white to off-white crystal powder Package: foil bag Uses: Treatment of primary focal advanced breast cancer. Letrozole is a non-steroidal aromatase inhibitor for the treatment of hormonally-responsive breast cancer after surgery. Letrozole is approved by the United States Food and Drug Administration (FDA) for the treatment of local or metastatic breast cancer that is hormone receptor positive or has an unknown receptor status in postmenopausal women. Letrozole has been used for ovarian stimulation because it has fewer side-effects than clomiphene (Clomid) and less chance of multiple gestation. The anti-estrogen action of letrozole has been shown to be useful in pretreatment for termination of pregnancy, in combination with misoprostol. Letrozole can be used in place of mifepristone. Letrozole is sometimes used as a treatment for gynecomastia, although Letrozole is probably most effective at this if caught in an early stage (such as in users of anabolic steroids ). Some studies have shown that letrozole can be used to promote spermatogenesis in male patients suffering from nonobstructive azoospermia. When used in combination with growth hormone, letrozole has been shown effective in one adolescent boy with a short stature.